Alpinia Biopharma Reema Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 25-06-2024
- Paid Up Capital ₹ 2.50 Cr
as on 25-06-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 186.95%
(FY 2021)
- Profit -212.99%
(FY 2021)
- Ebitda -124.64%
(FY 2021)
- Net Worth -37.51%
(FY 2021)
- Total Assets 43.66%
(FY 2021)
About Alpinia Biopharma Reema
The Corporate was formerly known as Alpinia Agri Tech Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 2.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Agrawal, Aditi Karandikar, Feng Xu, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74110DL2016PTC307373
- Company No.
307373
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2016
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alpinia Biopharma Reema?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anup Agarwal  | Director | Current | |
| Anil Agrawal | Director | 20-Oct-2016 | Current |
| Aditi Karandikar | Director | 23-Aug-2021 | Current |
Feng Xu  | Additional Director | 22-Aug-2018 | Current |
| Bhalchandra Karandikar | Additional Director | 22-Aug-2018 | Current |
Financial Performance and Corporate Structure Insights of Alpinia Biopharma Reema.
Alpinia Biopharma Reema Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 186.95% increase. The company also saw a substantial fall in profitability, with a 212.99% decrease in profit. The company's net worth observed a substantial decline by a decrease of 37.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alpinia Biopharma Reema?
In 2021, Alpinia Biopharma Reema had a promoter holding of 30.54% and a public holding of 69.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alpinia Biopharma Reema?
Unlock and access historical data on people associated with Alpinia Biopharma Reema, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alpinia Biopharma Reema, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alpinia Biopharma Reema's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
